rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

inTest Corporation

INTT · NYSE American

Health CareLife-science toolsNot moving yet

INTT stood above a rising 150-day average in 38 of the last 52 weekly readings, and has been out of that trend for the last 2 weeks. It is 6.7% below that average now. Life Science Tools & Research Services: 54% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 2
Industry in uptrend
54% +4 in 4 wk
Insider buys, 12 months
$45K
Insider sales, 12 months
$116K
Officials’ trades on record
0
Institutions holding
89 (+20)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 38 of 52 weeks.

20 Apr – 19 Oct
27%44%61%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$109K$0$61KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months3
Buyers · sellers1 · 1
WhoDidSharesTraded
Richard N. Grant, Jr.President & CEOsold1,636at $14.2818 Mar 2026filed 18 Mar 2026
Richard N. Grant, Jr.President & CEOsold1,397at $14.1611 Mar 2026filed 11 Mar 2026
Richard N. Grant, Jr.President & CEOsold1,097at $13.339 Mar 2026filed 11 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders89+20 on the quarter
New · exited35 · 16
Reported value$140.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
ROYCE & ASSOCIATES LPreduced · filed 14 Aug 20261,349,896$24.5M-82,000−5.7%
BlackRock, Inc.added · filed 7 Aug 2026936,047$17.0M+662,100+241.7%
First Eagle Investment Management, LLCadded · filed 5 Aug 2026612,602$11.1M+188,500+44.4%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026510,105$9.3M-95,421−15.8%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026502,237$9.1M+52,028+11.6%
DIMENSIONAL FUND ADVISORS LPreduced · filed 11 Aug 2026440,213$8.0M-26,184−5.6%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026285,517$5.2M+248,087+662.8%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026282,935$5.1M+154,495+120.3%
Pacific Ridge Capital Partners, LLCreduced · filed 12 Aug 2026248,275$4.5M-254,024−50.6%
BARD ASSOCIATES INCreduced · filed 12 Aug 2026210,598$3.8M-988−0.5%
31 Mar 2023 – 30 Jun 2026
436587Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Joseph W. Dews IV Company insiderDirector · last 9 Oct 20265 · 1
Steven J. Abrams Company insiderDirector · last 5 Oct 20260 · 0
Gerald J. Maginnis Company insiderDirector · last 17 Jun 20264 · 0
Karl E. Johnsen Company insiderDirector · last 17 Jun 20260 · 0
Joseph Richard McManus Jr. Company insiderDivision Pres-Electronic Test · last 28 Apr 20260 · 0
Richard B. Rogoff Company insiderPresident and CEO · last 28 Apr 20260 · 0
Richard N. Grant Jr. Company insiderPresident & CEO · last 31 Mar 20260 · 11
Michael F. Goodrich Company insiderDivision Pres-Process Tech · last 17 Mar 20260 · 0
Duncan Gilmour Company insiderCFO, Treasurer & Secretary · last 16 Mar 20260 · 0
Jeffrey A. Beck Company insiderDirector · last 16 Mar 20260 · 0
Michael Tanniru Company insiderDiv. President, Envir. Tech. · last 11 Jun 20250 · 0
Scott Eric Nolen Company insiderDivision Pres-Process Tech · last 10 Jan 20240 · 1

Same industry

OABI OmniAbLeading+67%
TXG 10x GenomicsLeading+59%
AVTR AvantorLeading+45%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+35%
MASS 908 DevicesLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202543.0%
Operating profit marginFY 2025 · to 31 Dec 2025-3.3%
Free cash flow marginFY 2025 · to 31 Dec 20255.0%
Return on capital employedFY 2025 · to 31 Dec 2025-3.2%
Debt to equityFY 2025 · to 31 Dec 20250.07×
Research spendFY 2025 · to 31 Dec 20258.3%
Share count trendFY 2025 · to 27 Feb 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$14.2M
Free cash flowFY 2025 · to 31 Dec 2025$5.7M

Analyst forecasts

No analyst forecasts yet.